DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
DURECT Corp (DRRX) Tops Q2 EPS by 7c
August 3, 2020 4:52 PM EDTDURECT Corp (NASDAQ: DRRX) reported Q2 EPS of $0.07, $0.07 better than the analyst estimate of $0.00. Revenue for the quarter came in at $25.8 million versus the consensus estimate of $11.48 million.
"We continued to make progress in our clinical programs investigating DUR-928, our lead epigenetic... More
